Effects of different doses of long-acting growth hormone in treating children with growth hormone deficiency

Figure 2 Alterations in Physiological Markers Following polyethylene glycol recombinant human growth hormone Treatment. A: Illustrates the variations in serum insulin-like growth factor-1 concentrations one-year post-treatment with polyethylene glycol recombinant human growth hormone (PEG-rhGH) at different doses; B: Depicts changes in serum insulin-like growth factor-binding protein-3 levels one year after treatment with PEG-rhGH at varying doses; C: Showcases the modifications in bone age one year after treatment with PEG-rhGH at diverse doses. HDG: High-dose group; LDG: Low-dose group; IGF-1: Insulin-like growth factor-1; IGFBP-3: Insulin-like growth factor-binding protein-3; BA: Bone age; CA: Chronological age.